Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2018-12-20 Regulatory Filings
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
ArcticZymes and Vectron Biosolutions sign license agreement on recombinant enzyme expression technology
Regulatory Filings Classification · 95% confidence The document is a press release dated December 20, 2018, announcing that ArcticZymes (a subsidiary of Biotec Pharmacon) signed a nonexclusive license agreement with Vectron Biosolutions regarding recombinant enzyme expression technology. This announcement details a business development, specifically a licensing deal and associated financial terms (royalties). This type of corporate action—a strategic agreement or partnership announcement—does not fit neatly into the specific financial reporting categories (10-K, IR, ER, etc.). It is a general corporate announcement. Given the available options, the most appropriate classification for a significant, non-standard corporate event announcement that isn't explicitly covered by other codes (like M&A, Capital Change, or Director Dealing) is the general Regulatory Filings category (RNS), which serves as a fallback for miscellaneous regulatory announcements.
2018-12-20 English
ArcticZymes and Vectron Biosolutions sign license agreement on recombinant enzyme expression technology
Regulatory Filings Classification · 90% confidence The document announces a non-exclusive license agreement between ArcticZymes and Vectron Biosolutions regarding enzyme expression technology. This is a specific business development event, not a standard periodic financial report (like 10-K, IR, ER) or a formal regulatory filing like a proxy statement or insider trade report. It details a strategic partnership and commercial arrangement. Since there is no specific category for 'Business Development' or 'License Agreement,' and it is not a general regulatory announcement (RNS) or a capital/financing update (CAP), the most appropriate classification among the provided options is the general 'Regulatory Filings' (RNS) as a catch-all for significant, non-standard corporate news, or potentially 'LTR' if the agreement was the result of prior legal/dispute resolution, which is not indicated. Given the nature of the announcement (a strategic commercial agreement), and lacking a better fit, RNS is the most suitable fallback for significant corporate news that doesn't fit the defined financial/governance categories. However, upon re-evaluation, this type of announcement often falls under general corporate news releases. Since RNS is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' it is the best fit here.
2018-12-20 English
ArcticZymes signs new supply agreement for enzyme, Cod UNG
Regulatory Filings Classification · 99% confidence The document announces a specific business event: ArcticZymes (a subsidiary of Biotec Pharmacon) signing a new supply agreement for an enzyme product (Cod UNG) with a Japanese company, including projected revenue figures. This is a material business development announcement. It is not a full annual report (10-K), an earnings release (ER) which focuses on financial statements, or a transcript (CT). It is a specific corporate action announcement. Since there is no specific category for 'Supply Agreement Announcement' or 'Material Business Update', and it is not a director's dealing (DIRS), capital change (CAP/SHA), or dividend notice (DIV), the most appropriate general category for a significant, non-standard regulatory update that doesn't fit elsewhere is Regulatory Filings (RNS). However, given the content is a press release detailing a commercial contract and revenue outlook, it strongly resembles an announcement that would typically be filed under a general regulatory disclosure mechanism, which RNS covers as a fallback. If a more specific category like 'Material Contract' existed, it would fit there, but RNS serves as the best fit among the provided options for a general, material business announcement.
2018-12-13 English
ArcticZymes signs new supply agreement for enzyme, Cod UNG
Regulatory Filings Classification · 100% confidence The document is a short press release dated December 13, 2018, announcing a new supply agreement for an enzyme product (Cod UNG) between ArcticZymes and a Japanese company. It details the expected revenue and includes quotes from management. This type of announcement, which is not a formal financial report (like 10-K or IR), a dividend notice, or a management change, falls best under the general category of a Regulatory Filing or a specific announcement related to business operations. Since it is a specific business development announcement (a contract signing) and not a general regulatory filing fallback (RNS), and it doesn't fit any other specific category (like M&A, Capital Change, or Earnings), it is best classified as a general announcement. Given the options, and since it is a specific business update that isn't a formal report, 'Regulatory Filings' (RNS) is the most appropriate general category for non-standard, material business news releases if a more specific category like 'TAR' (M&A) or 'CAP' (Financing) is not applicable. However, upon reviewing the definitions, none perfectly capture a 'Supply Agreement Announcement'. Since it is a material business update, and not a report itself, RNS is the fallback for miscellaneous regulatory/material announcements. Given the context of financial reporting databases, these types of press releases often default to RNS if no other category fits.
2018-12-13 English
Biotec Pharmacon - Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is titled 'Biotec Pharmacon - Mandatory notification of trade' and explicitly states that an executive (Rolf E. Engstad, CSO) purchased shares in the company. This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The appropriate code is DIRS.
2018-11-14 English
Biotec renews clinical trial agreement with Memorial Sloan Kettering Cancer Center
Regulatory Filings Classification · 85% confidence The document is a short press release announcing the renewal of a clinical trial agreement (CTA) between Biotec BetaGlucans and Memorial Sloan Kettering Cancer Center regarding a neuroblastoma vaccine trial. It details the scope of the agreement (drug supply, data sharing, IP rights) and provides an update on patient recruitment. This type of announcement, concerning ongoing research, legal/contractual arrangements related to development, and operational updates that do not fit neatly into standard financial reports (10-K, ER, IR), is best classified as a general Regulatory Filing or announcement. Given the specific options, it is not an ER, IR, 10-K, or a specific legal proceeding report (LTR), but rather a general operational update that might be filed with regulators or exchanges. Since it is a specific announcement about a contract/trial update, and not a standard financial report, the most appropriate general category is Regulatory Filings (RNS), as it doesn't fit the other specific operational/financial codes.
2018-11-13 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.